Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
LFVN · Nasdaq · United States · Pharmaceutical Preparations
In shortLifevantage Corp is profitable.
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 3.3% | 28/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 2.8% | 31/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 14.9% | 74/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.89× | 91/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -1.63 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 3.7% | 35/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.32× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 12.7% | 64/100 |
| Operating margin volatility | 1.3% | 97/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -5.1% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | 26.0% | 100/100 |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 206 | 213 | 200 | 229 | 183 |
| Cost of revenue | 38 | 43 | 41 | 45 | 41 |
| Gross profit | 168 | 170 | 159 | 184 | 142 |
| Research & development | 0.7 | 0.6 | 0.7 | 1.4 | 1 |
| Selling, general & admin | 63 | 71 | 68 | 69 | 58 |
| Operating income | 7.6 | 4.3 | 4.3 | 12 | 6.1 |
| Interest expense | 0 | (0.2) | (0.4) | – | – |
| Pre-tax income | 4.7 | 4 | 4.4 | 12 | 6.1 |
| Income tax | 1.6 | 1.5 | 1.4 | 2.4 | 1 |
| Net income | 3.1 | 2.5 | 2.9 | 9.8 | 5.1 |
| Diluted EPS | $0.24 | $0.20 | $0.23 | $0.75 | $0.40 |
| Diluted shares (millions) | 13 | 13 | 13 | 13 | 13 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of Lifevantage Corp are included in the Investor plan. Try free for 7 days →
−1.63 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 27, 2026